NYHA class | III | II | III | IV | III | III | III | III |
FEV1 | | | | | | | | |
L | 1.46 | 1.21 | 1.33 | 1.22 | 0.56 | 0.64 | 0.58 | 0.71 |
% | 45 | 40 | 44 | 41 | 36 | 40 | 37 | 50 |
PH therapy | None | Sildenafil | Sildenafil | Sildenafil | None | Sildenafil | Sildenafil and bosentan | Sildenafil and bosentan |
Oxygen supplementation at rest L·min−1 | 5 | 5 | 5 | 12 | 3 | 3 | 4 | 4 |
PaO2 on oxygen mmHg | 66 | 79 | 61 | 51# | 88 | 63 | 82 | 76 |
6-MWD m | 300 | 330 | 270 | 120 | 180 | 180 | 186 | 243 |
Saturation at end of 6-MWT | | | | | | | | |
% | 78 | 82 | 79 | 70 | 86 | 76 | 80 | 96 |
Oxygen supplementation L·min−1 | 6 | 5 | 6 | 12 | 4 | 4 | 6 | 6 |
PAP systolic/diastolic/mean mmHg | 51/18/36 | 50/24/37 | 51/18/35 | 57/39/45 | 55/16/35 | 41/16/24 | 33/19/24 | 33/18/23 |
Cardiac index L·min−1·m−2 | 3.24 | 3.62 | 3.30 | 5.52 | 3.24 | 2.73 | 4.73 | 3.60 |
PVR dyn·s·cm−5 | 360 | 355 | 340 | 265 | 372 | 332 | 147 | 148 |
NT-proBNP serum level pg·mL−1 | 130 | 160 | 110 | 150 | 159 | 137 | 201 | 154 |
Right ventricular ejection fraction % | 31 | N/A | 33 | 28 | 32 | 33 | 37 | 35 |
Change in therapy | Initiation of sildenafil | No change | No change | Discontinuation of sildenafil | Initiation of sildenafil | Initiation of bosentan | No change | No change |